Innovative drug delivery platform based on biocompatible poly(2-oxazoline)s block copolymers is proposed to improve chemotherapy of cancer. The technology will overcome major therapeutic challenges in breast cancer. This will be realized by tailoring poly(2-oxazoline)s structure to incorporate very large amounts (>40 wt. %) of insoluble drugs in polymer micelles of narrow size distribution (20-50 nm). These high-capacity micelles can be lyophilized and re-dispersed without loss of the particle size, drug loading or drug activity. The micelles will carry paclitaxel and docetaxel using drastically less amount of excipients relative to current formulations. Hence, excipient-associated toxicities will be decreased. The micelles will be targeted using monoclonal antibodies to Her2-receptors. This strategy is expected to address Herceptin resistance in cancers overexpressing Her2. The proposed aims will 1) optimize poly(2-oxazoline)s structures for solubilization of water-insoluble drugs;2) determine pharmacokinetics and maximum tolerated doses in vivo;3) validate anti-tumor activity in mouse models of breast cancer, and 4) develop targeted micelles effective against Herceptin sensitive and resistant tumors. This CNPP joins together pharmaceutical scientists at [deleted], cancer researchers at [deleted], and polymer chemists at [deleted] who will contribute to the Alliance through challenge projects and other trans-alliance activities.

Public Health Relevance

Overcoming the historical limitations of dose-limiting toxicities, life-threatening side effects, and low water solubility of potentially highly-active drug candidates could result in the development of effective drug delivery systems that provide safety, bioavailability, and ease of use.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project--Cooperative Agreements (U01)
Project #
5U01CA151806-05
Application #
8717603
Study Section
Special Emphasis Panel (ZCA1-SRLB-X (M1))
Program Officer
Farrell, Dorothy F
Project Start
2010-09-02
Project End
2015-07-31
Budget Start
2014-08-01
Budget End
2015-07-31
Support Year
5
Fiscal Year
2014
Total Cost
$379,186
Indirect Cost
$93,372
Name
University of North Carolina Chapel Hill
Department
Pharmacology
Type
Schools of Pharmacy
DUNS #
608195277
City
Chapel Hill
State
NC
Country
United States
Zip Code
27599
Alakhova, Daria Y; Kabanov, Alexander V (2014) Pluronics and MDR reversal: an update. Mol Pharm 11:2566-78
Helikar, Tomas; Kochi, Naomi; Kowal, Bryan et al. (2013) A comprehensive, multi-scale dynamical model of ErbB receptor signal transduction in human mammary epithelial cells. PLoS One 8:e61757
Mohapatra, Bhopal; Ahmad, Gulzar; Nadeau, Scott et al. (2013) Protein tyrosine kinase regulation by ubiquitination: critical roles of Cbl-family ubiquitin ligases. Biochim Biophys Acta 1833:122-39
Schneider, Maximilian; Fetsch, Corinna; Amin, Ihsan et al. (2013) Polypeptoid brushes by surface-initiated polymerization of N-substituted glycine N-carboxyanhydrides. Langmuir 29:6983-8
Zhao, Yi; Alakhova, Daria Y; Kim, Jong Oh et al. (2013) A simple way to enhance Doxil® therapy: drug release from liposomes at the tumor site by amphiphilic block copolymer. J Control Release 168:61-9
Alakhova, Daria Y; Zhao, Yi; Li, Shu et al. (2013) Effect of doxorubicin/pluronic SP1049C on tumorigenicity, aggressiveness, DNA methylation and stem cell markers in murine leukemia. PLoS One 8:e72238
Chen, Tao; Amin, Ihsan; Jordan, Rainer (2012) Patterned polymer brushes. Chem Soc Rev 41:3280-96
Zhao, Xiangshan; Malhotra, Gautam K; Band, Hamid et al. (2012) Derivation of myoepithelial progenitor cells from bipotent mammary stem/progenitor cells. PLoS One 7:e35338
Batrakova, Elena V; Gendelman, Howard E; Kabanov, Alexander V (2011) Cell-mediated drug delivery. Expert Opin Drug Deliv 8:415-33
Luxenhofer, Robert; Sahay, Gaurav; Schulz, Anita et al. (2011) Structure-property relationship in cytotoxicity and cell uptake of poly(2-oxazoline) amphiphiles. J Control Release 153:73-82